10445-91-7

Usage

Uses

Used in Pharmaceutical Industry:
4-(Chloromethyl)pyridine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific therapeutic properties, contributing to the advancement of medicine and healthcare.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(Chloromethyl)pyridine serves as a crucial building block for the creation of novel agrochemicals. Its incorporation into these compounds can enhance their effectiveness in protecting crops from pests and diseases, thereby improving agricultural productivity and food security.
Used in Organic Synthesis:
4-(Chloromethyl)pyridine is utilized as a versatile reagent in organic synthesis, enabling the formation of a wide range of complex organic compounds. Its presence in these reactions can facilitate the creation of new molecules with diverse applications, such as in materials science, chemical research, and the development of new technologies.
Overall, 4-(Chloromethyl)pyridine is a valuable chemical compound with diverse applications across various industries, particularly in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. Its unique structure and reactivity make it an essential component in the development of innovative products and solutions. However, its potential health risks necessitate proper handling and safety precautions to ensure the well-being of those working with 4-(Chloromethyl)pyridine.

Upstream product

• 586-95-8 pyridine-4-methanol 
• 1003-67-4 4-methylpyridine-1-oxide 
• 74405-07-5 4-chloro-2,2-dimethyl-2H-benzo[e][1,3]oxazine 
• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 
• 1570-45-2 isonicotinic acid ethylester 
• 1822-51-1 4-picolylchloride hydrochloride 
• 244-99-5 4-azafluorene 
• 872-85-5 pyridine-4-carbaldehyde 

Downstream Products

• 58414-97-4 4-(4-methylphenylsulfonylmethyl)pyridine 
• 3034-32-0 N-((pyridin-4-yl)methyl)benzenamine 
• 132312-62-0 N-[(4-pyridyl)methyl]pyrrolidin-2-one 
• 122955-42-4 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone 
• 181418-37-1 4-(2-bromo-6-methoxyphenoxymethyl)pyridine 
• 1053645-74-1 (4R,5S,6S,7R)-4,7-Dibenzyl-5,6-bis-(2-methoxy-ethoxymethoxy)-1-naphthalen-2-ylmethyl-3-pyridin-4-ylmethyl-[1,3]diazepan-2-one 
• 191873-50-4 4-(2-Iodo-6-methoxy-phenoxymethyl)-pyridine 
• 203002-16-8 3-(3-Cyclopentyloxy-4-methoxy-phenyl)-3-pyridin-4-ylmethyl-1,3-dihydro-indol-2-one 
• 203440-78-2 3-(3-cyclopentyloxy-4-methoxy-phenyl)-2-oxo-3-pyridin-4-ylmethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 181040-22-2 2-Fluoro-4-(pyridin-4-ylmethoxy)benzonitrile 
• 108-89-4 picoline 
• 20151-37-5 rac-1-phenyl-2-(4-pyridyl)ethanol 
• 181039-80-5 methyl (RS)-(2-chlorophenyl)-[2-cyano-5-(pyridin-4-ylmethoxy)phenoxy]acetate 
• 325464-16-2 Boc-Tyr-(O-Pic)-NH(CH₂)2CH(CH₃)2 

Relevant academic research and scientific papers

Efficient synthesis of a new series of piperidine ring-modified analogs of (±)-threo-methyl phenyl(piperidin-2-yl)acetate

A series of novel piperidine ring modified analogs of (±)-threo- methyl phenyl (piperidin-2-yl)acetate was synthesized by direct alkylation and reductive amination procedure, using sodium borohydride over molecular sieves. The chemical structures of these compounds were established based on mass spectra, 1H NMR spectra, and CHN elemental analysis data. Several significant modifications in the literature methodologies were made to make the reaction more efficient, and good yields were generally obtained. Copyright Taylor & Francis Group, LLC.

A multifunctional Eu-based coordination polymer luminescent sensor for highly sensitive and selective detection of Fe3+ and acetone

A new 3D Eu-based coordination polymer, ([Eu(L)(H2O)3]Cl·H2O)n (1) (H2L = (4-(pyridyl-N-oxide)methylphosphonic acid), was successfully self-assembled via diffusion method at room temperature and characterized by single-crystal X-ray diffraction, elemental analyses, powder X-ray diffraction, thermogravimetric analyses and FT-IR. Single-crystal X-ray diffraction analysis shows that 1 features 3D (4,5)-connected (3·4·5·62·7)(32·42·5·63·72) topological framework with large 1D channels. Photoluminescent spectra of 1 exhibit the strong characteristic luminescence of Eu3+. More importantly, sensing experiments exhibit that 1 can be used as a fluorescence sensor for detecting Fe3+ and acetone with excellent sensitivity, great selectivity, reproducibility and low detection limits for Fe3+, and acetone are 0.21 μM and 0.0246 vol percent. It is the first example of Eu-based phosphonate sensor for simultaneous detection of Fe3+ and acetone.

Structure-guided optimization of 1H-imidazole-2-carboxylic acid derivatives affording potent VIM-Type metallo-β-lactamase inhibitors

Production of metallo-β-lactamases (MBLs) in bacterial pathogens is an important cause of resistance to the ‘last-resort’ carbapenem antibiotics. Development of effective MBL inhibitors to reverse carbapenem resistance in Gram-negative bacteria is still needed. We herein report X-ray structure-guided optimization of 1H-imidazole-2-carboxylic acid (ICA) derivatives by considering how to engage with the active-site flexible loops and improve penetration into Gram-negative bacteria. Structure-activity relationship studies revealed the importance of appropriate substituents at ICA 1-position to achieve potent inhibition to class B1 MBLs, particularly the Verona Integron-encoded MBLs (VIMs), mainly by involving ingenious interactions with the flexible active site loops as observed by crystallographic analyses. Of the tested ICA inhibitors, 55 displayed potent synergistic antibacterial activity with meropenem against engineered Escherichia coli strains and even intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL. The morphologic and internal structural changes of bacterial cells after treatment further demonstrated that 55 crossed the outer membrane and reversed the activity of meropenem. Moreover, 55 showed good pharmacokinetic and safety profile in vivo, which could be a potential candidate for combating VIM-mediated Gram-negative carbapenem resistance.

Application of 1-substituted-1H-imidazole-2-carboxylic acid compounds in preparation of metal beta-lactamase inhibitors

The invention relates to application of 1-substituted-1H-imidazole-2-carboxylic acid compounds in preparation of metal beta-lactamase inhibitors, and particularly discloses application of compounds shown in a formula I in preparation of metal beta-lactamase inhibitors or antibacterial combined medicines. Experiments prove that the compounds provided by the invention can be used for effectively inhibiting the activity of various MBL enzymes including VIM-2, NDM-1, IMP-1, VIM-1 and VIM-5; the compounds, especially the compounds 11, 13, 14, 29, 30, 34, 37 and 40, have an IC50 value of 2.13 [mu] Mor less on the VIM-2 type MBL enzymes, have a more significant inhibition effect than positive control drugs, and have very good potential in the preparation of MBL enzyme inhibitors. Meanwhile, thecompounds disclosed by the invention are combined with beta-lactam antibiotics, so that metal beta-lactamase generated by drug-resistant bacteria can be effectively inhibited, the antibacterial activity of the antibiotics is enhanced, and the compounds have a very good application prospect in preparation of antibacterial combined medicines.

1 - Substituted - 111H-imidazol -2 - carboxylic acid compound (by machine translation)

The invention relates to 1 - substituted - 111H-imidazol -2 - carboxylic acid compounds. Experiments prove that the compound provided by the invention can effectively inhibit the activity of various MBL enzymes including VIM-2, NDM-1, ?currcurrcurrcurry ?, VIM-IMP-1 1 and VIM IM IM, especially compounds 11 and 13, 14, 29, 30, 34, 37, 40, and IC of VIM-2 type MBL enzyme. 50 The value is below 2.13 μm, the inhibition effect is more remarkable than that of the positive control medicine, and the MBL enzyme inhibitor has great potential in preparing the MBL enzyme inhibitor. , The compound is combined with β - lactam antibiotics, metal β - lactamase produced by drug-resistant bacteria can be effectively inhibited, the antibacterial activity of the antibiotic is enhanced, and the compound has a very good application prospect in preparation of antibacterial and combined medicines. (by machine translation)

Thiourea-Mediated Halogenation of Alcohols

The halogenation of alcohols under mild conditions expedited by the presence of substoichiometric amounts of thiourea additives is presented. The amount of thiourea added dictates the pathway of the reaction, which may diverge from the desired halogenation reaction toward oxidation of the alcohol, in the absence of thiourea, or toward starting material recovery when excess thiourea is used. Both bromination and chlorination were highly efficient for primary, secondary, tertiary, and benzyl alcohols and tolerate a broad range of functional groups. Detailed electron paramagnetic resonance (EPR) studies, isotopic labeling, and other control experiments suggest a radical-based mechanism. The fact that the reaction is carried out at ambient conditions, uses ubiquitous and inexpensive reagents, boasts a wide scope, and can be made highly atom economic, makes this new methodology a very appealing option for this archetypical organic reaction.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.

MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).

Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides

TTK kinase was identified by in-house siRNA screen and pursued as a tractable, novel target for cancer treatment. A screening campaign and systematic optimization, supported by computer modeling led to an indazole core with key sulfamoylphenyl and acetamido moieties at positions 3 and 5, respectively, establishing a novel chemical class culminating in identification of 72 (CFI-400936). This potent inhibitor of TTK (IC50 = 3.6 nM) demonstrated good activity in cell based assay and selectivity against a panel of human kinases. A co-complex TTK X-ray crystal structure and results of a xenograft study with TTK inhibitors from this class are described.